From Nasdaq: 2025-05-02 17:48:00

Viking Therapeutics (NASDAQ: VKTX) saw a significant increase in its stock price this week, rising by almost 18% due to its weight-loss drug development. The World Health Organization (WHO) is set to support obesity drugs, aiming to improve access for lower- and middle-income patients. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are leading the market in weight-loss drugs in the U.S., with Viking’s VK2735 showing promise in phase 2 trials. WHO’s endorsement will further boost the global market for these medications.

Considering investing in Viking Therapeutics? The Motley Fool’s Stock Advisor team recommends 10 other stocks for potential high returns, excluding Viking. The Stock Advisor’s average return is 889%, outperforming the S&P 500 significantly. Join Stock Advisor to access the latest top 10 list and potentially benefit from market-crushing returns.



Read more at Nasdaq: Why Viking Therapeutics Stock Was Victorious This Week